Shorts:  

• The first study highlights the analytical assessment results of SB17 vs Stelara (ustekinumab) which demonstrated on SB17 to biologically similar to Stelara in terms of its physicochemical, structural & biological attributes 
• Additionally, the data supports the similarity of SB17 with reference Stelara in terms of the biosimilarity, PK, PD, clinical effect in patients suffering from moderate-to-severe psoriasis  
• Samsung Bioepis has recently signed a collaborative agreement with Sandoz to commercialize SB17 across the US, EU, UK, Canada & Switzerland

Ref: Samsung Bioepis | Image: Samsung Bioepis

Related News:- Samsung Bioepis Successfully Resolves Patent Disputes with Johnson & Johnson

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.comSamsung Bioepis, SB17, Ustekinumab, Crohn's diseases, Biosimilar, Partnership, Switzerland, Canada, EU, US, ECCO